Incremental dialysis to improve health outcomes for kidney failure patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The INCH-HD trial aims to evaluate whether incremental haemodialysis (HD) can preserve the quality of life for patients starting dialysis compared to conventional HD. This international, multicentre, prospective, adaptive, randomised, open-label trial will assess the non-inferiority of incremental HD in terms of quality of life outcomes measured at six months. The study addresses the high mortality and burden associated with traditional HD by exploring a potentially safer and more patient-friendly approach. Participants will be randomly assigned to either incremental or conventional HD to determine the best treatment strategy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults (≥ 18 years of age) and
2. Commencing HD as their initial dialysis therapy and
3. Able to give informed consent

Exclusion Criteria:

1. Urine output \<0.5Litres/day
2. Unlikely to be on HD for ≥1 year.

Where it's running

• Concord Repatriation General Hospital
  Concord, New South Wales, Australia Recruiting
• St George Hospital
  Kogarah, New South Wales, Australia Recruiting
• Liverpool Hospital
  Liverpool, New South Wales, Australia Recruiting
• John Hunter Hospital
  New Lambton Heights, New South Wales, Australia Recruiting
• Port Macquarie Hospital
  Port Macquarie, New South Wales, Australia Recruiting
• Bundaberg Hospital
  Bundaberg, Queensland, Australia Recruiting

Study contacts

• Principal investigator: Peter Kerr, Prof — University of Queensland, Monash University
• Study coordinator: Lisan Mulvey
• Email: inch-hd.trial@uq.edu.au
• Phone: +61 417 690 237

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Omnisol-preserved kidneys before transplant (hypothermic machine perfusion)

  This study tests whether using Omnisol during hypothermic machine perfusion before kidney transplant can improve early graft function compared with standard preservation.

  Recruiting Vivalyx GmbH · Rotterdam · NCT07792317

• Kidney and liver blood flow patterns after major trauma

  We will use bedside ultrasound to see whether abnormal kidney and liver blood flow patterns occur in adults admitted to the ICU after major trauma and whether those patterns link to acute kidney injury or the need for mechanical ventilation.

  Recruiting Azienda Usl di Bologna · Bologna · NCT07492511

• Home-based exercise to boost fitness for people waiting for a kidney transplant

  This study tests whether a 12-week, home-based exercise program plus a wearable activity tracker helps adults on the kidney transplant waiting list increase daily activity and improve physical function.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07446296

• CRISPR-edited donor kidney transplant to reduce rejection risk

  This trial will see if donor kidneys edited with CRISPR to turn off key HLA genes can lower rejection in adults with end-stage kidney disease receiving transplants.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053462

• Effect of Daratumumab on Kidney Diseases Related to Monoclonal Gammopathy

  This study is testing whether daratumumab can help improve kidney function and overall health in people with kidney diseases linked to monoclonal gammopathy.

  Recruiting Phase 2 Helsinki University Central Hospital · Helsinki · NCT06889948

• Examining amino acid loss in patients undergoing kidney treatment

  This study looks at how much amino acid is lost in patients receiving kidney treatment in the ICU compared to those who aren't, to help improve nutrition for people with kidney problems.

  Recruiting Medical University of Vienna · Vienna, State of Vienna · NCT06659835

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.